DEPARTMENT OF HEALTH

NOTICE OF EMERGENCY AND PROPOSED RULEMAKING

The Director of the Department of Health, pursuant to the authority set forth in § 201(a) of the District of Columbia Uniform Controlled Substances Act of 1981, effective August 5, 1981 (D.C. Law 4-29; D.C. Official Code § 48-902.01(a) (2012 Repl.)) and Mayor's Order 98-49, dated April 15, 1998, hereby gives notice of the adoption, on an emergency basis, of the following amendments to Chapter 12 (Controlled Substances Act Rules) of Subtitle B (Public Health & Medicine) of Title 22 (Health) of the District of Columbia Municipal Regulations (DCMR).

The emergency and proposed rules would amend the list of drugs on Schedules I through V.

Emergency action is necessary because a substantial part of the revised schedule is the addition of numerous cannabimimetic drugs that have no legitimate medical use, are readily available, and pose an immediate risk to public health and safety because of their harmful effects when abused. Those effects of abuse include vomiting, anxiety, agitation, irritability, seizures, hallucinations, tachycardia, elevated blood pressure, and loss of consciousness.

The emergency rulemaking was adopted on June 20, 2014, became effective immediately, and will remain in effect for one hundred twenty (120) days, until October 18, 2014, unless superseded by publication of a Notice of Final rulemaking in the *D.C. Register*. The Director also gives notice of his intent to take final rulemaking action to adopt the amendments in not less than thirty (30) days from the date of publication of this notice in the *D.C. Register*.

Chapter 12 (Controlled Substances Act Rules) of 22-B DCMR (Public Health & Medicine) is amended to read as follows:

CHAPTER 12 CONTROLLED SUBSTANCES ACT RULES

1200 PURPOSE

1200.1 This chapter shall comprise all the enumerated schedules of controlled substances under the District of Columbia Uniform Controlled Substances Act of 1981 (Act), effective August 5, 1981 (D.C. Law 4-29; D.C. Official Code § 48-902.01), and all final rulemakings made by the Mayor or designee that add, delete, or reschedule a controlled substance under the authority of Section 201 of the Act (D.C. Official Code § 48-902.01).

1201 SCHEDULE I ENUMERATED

1201.1 The controlled substances listed in this section are included in Schedule I of the Act unless removed therefrom pursuant to Section 201 of the Act:

(a) Opiates: Unless specifically excepted or unless listed in another schedule, any of the following opiates including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:

(1) 1-Methyl-4-phenyl-4-propionoxypiperidine (MPPP);

(2) 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);

(3) 3-Methylfentanyl;

(4) 3-Methylthiofentanyl;

(5) Acetyl-Alpha-Methylfentanyl;

(6) Acetylmethadol;

(7) Allylprodine;

(8) Alphacetylmethadol except Levo-alphacetylmethadol

(9) Alphameprodine;

(10) Alphamethadol;

(11) Alpha-Methylfentanyl;

(12) Alpha-Methylthiofentanyl;

(13) Benzethidine;

(14) Betacetylmethadol;

(15) Beta-hydroxyfentanyl;

(16) Beta-hydroxy-3-Methylfentanyl;

(17) Betameprodine;

(18) Betamethadol;

(19) Betaprodine;

(20) Clonitazene;

(21) Dextromoramide;

(22) Diampromide;

(23) Diethylthiambutene;

(24) Difenoxin;

(25) Dimenoxadol;

(26) Dimepheptanol;

(27) Dimethylthiambutene;

(28) Dioxaphetyl butyrate;

(29) Dipipanone;

(30) Ethylmethylthiambutene;

(31) Etonitazene;

(32) Etoxeridine;

(33) Furethidine;

(34) Hydroxypethidine;

(35) Ketobemidone;

(36) Levomoramide;

(37) Levophenacylmorphan;

(38) Morpheridine;

(39) Noracymethadol;

(40) Norlevorphanol;

(41) Normethadone;

(42) Norpipanone;

(43) Para-fluorofentanyl;

(44) Phenadoxone;

(45) Phenampromide;

(46) Phenomorphan;

(47) Phenoperidine;

(48) Piritramide;

(49) Proheptazine;

(50) Properidine;

(51) Propiram;

(52) Racemoramide;

(53) Thiofentanyl;

(54) Thiophene;

(55) Tilidine; and

(56) Trimeperidine;

(b) Opium Derivates: Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Acetorphine;

(2) Acetyldihydrocodeine;

(3) Benzylmorphine;

(4) Codeine methylbromide;

(5) Codeine-N-Oxide;

(6) Cyprenorphine;

(7) Desomorphine;

(8) Diacetylmorphine (heroin);

(9) Dihydromorphine;

(10) Drotebanol;

(11) Etorphine (except hydrochloride salt);

(12) Hydromorphinol;

(13) Methyldesorphine;

(14) Methyldihydromorphine;

(15) Morphine methylbromide;

(16) Morphine methylsulfonate;

(17) Morphine-N-Oxide;

(18) Myrophine;

(19) Nicocodeine;

(20) Nicomorphine;

(21) Normorphine;

(22) Pholcodine; and

(23) Thebacon;

(c) Hallucinogenic Substances: Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, its salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation (for the purposes of this paragraph only, the term "isomer" includes the optical, position, and geometric isomers):

(1) 1-[1-(2-Thienyl)cyclohexyl]piperidine;

(2) 1- [1-(2-thienyl)cyclohexyl]pyrrolidine;

(3) 1-(1-Phenylcyclohexyl)-pyrrolidine,Pyrrolidine analog of phencyclidine, PCPy, PHP;

(4) (2C-C) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine;

(5) (2C-D) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine;

(6) (2C-E) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine;

(7) (2C-H) 2-(2,5-Dimethoxyphenyl)ethanamine;

(8) (2C-I) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine;

(9) (2C-N) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine;

(10) (2C-P) 2-(2,5-Dimethoxy-4(n)-propylphenyl)ethanamine;

(11) (2C-T-2) 2-[4-(ethylthio)-2,5-dimethoxyphenyl)ethanamine;

(12) (2C-T-4)2-[4-(Isopropylthio)-2,5-dimethoxyphenyl] ethanamine;

(13) (2C-T-7) 2,5-Dimethoxy-4-(n)-propylthiophenethylamine);

(14) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25B-NBOMe);

(15) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine 25C-NBOMe); and

(16) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe);

(17) 2,5-Dimethoxyamphetamine;

(18) 2,5-Dimethoxy-4-ethylamphetamine;

(19) 3,4-Methylenedioxymethamphetamine;

(20) 3,4-Methylenedioxyamphetamine;

(21) 3,4-Methylenedioxy-N-ethylamphetamine;

(22) 3,4,5-Trimethoxyamphetamine;

(23) 4-Bromo-2,5-dimethoxy-amphetamine;

(24) 4-Bromo-2,5-dimethoxyphenethylamine;

(25) 4-Methoxyamphetamine;

(26) 4-Methylaminorex;

(27) 4-Methyl-2,5-dimethoxyamphetamine;

(28) 5-flouro-UR-144 and XLR11[1-(5-Fluoro-pentyl)1Hindol-3-yl](2,2,3,3- tetramethylcyclopropyl)methanone;

(29) 5-Methoxy-3,4-methylenedioxyamphetamine;

(30) 5-Methoxy-N,N-diisopropyltryptamine (other name: 5-MeO-DIPT);

(31) 5-Methoxy-N,N-dimethyltryptamine;

(32) Bufotenine;

(33) Diethyltryptamine;

(34) Dimethyltryptamine;

(35) N-Ethyl-1-phenylcyclohexylamine;

(36) Ibogaine;

(37) Lysergic acid diethylamide;

(38) Mescaline;

(39) N-Ethyl-1-phenylcyclohexylamine;

(40) N-Ethyl-3-piperidyl benzilate;

(41) N-Methyl-3-piperidyl benzilate;

(42) Parahexyl--7374; some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6Hdibenzo[b,d]pyran; Synhexyl;

(43) Peyote;

(44) Psilocybin;

(45) Psilocyn; and

(46) Thiophene analog of phencyclidine;

(d) Depressants: Unless specifically excepted or unless listed in another schedule, any material, compound, or mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system including its salts, isomers, and salts of isomers, whenever the existence of the salts, isomers, and salts of isomers is possible, within the specific chemical designation:

(1) Gamma-Hydroxybutyric Acid [other names include GHB; gamma- hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium xybutyrate];

(2) Mecloqualone; and

(3) Methaqualone;

(e) Stimulants: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

(1) Alpha-ethyltryptamine;

(2) Alpha-methyltryptamine;

(3) Aminorex;

(4) Cathinone;

(5) Fenethylline;

(6) Mephedrone (4-methyl-N-methylcathinone);

(7) Methcathinone;

(8) Methylenedioxypyrovalerone (MDPV);

(9) Methylone;

(10) N-Benzylpiperazine;

(11) N-ethylamphetamine;

(12) N-Hydroxy-3,4-methylenedioxyamphetamine; and

(13) N,N-Dimethylamphetamine; and

(14) 4-methyl-N-ethylcathinone ("4-MEC")

(15) 4-methyl-alpha-pyrrolidinopropiophenone ("4-MePPP")

(16) Alpha-pyrrolidinopentiophenone ("α-PVP")

(17) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one ("butylone")

(18) 2-(methylamino)-1-phenylpentan-1-one ("pentedrone")

(19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one ("pentylone")

(20) 4-fluoro-N-methylcathinone ("4-FMC")

(21) 3-fluoro-N-methylcathinone ("3-FMC")

(22) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one ("naphyrone")

(23) Alpha-pyrrolidinobutiophenone ("α-PBP")

(f) Synthetic cannabinoids: Unless specifically exempted or unless listed in another schedule, any material, mixture, preparation, any compound structurally derived from, or that contains any quantity of the following synthetic substances, its salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation (for the purposes of this paragraph only, the term "isomer" includes the optical, position, and geometric isomers):

(1) Classified Synthetic Cannabinoids:

(A) Adamantoylindoles or adamantoylindazoles, including adamantyl carboxamide indoles and adamantyl carboxamide indazoles, or any compound structurally derived from 3-(1-adamantoyl) indole, 3-(1-adamantoyl)indazole, 3-(2-adamantoyl)indole, N-(1-adamantyl)-1H-indole-3-carboxamide, or N-(1-adamantyl)-1H-indazole-3-carboxamide by substitution at the nitrogen atom of the indole or indazole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-

methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole or indazole ring to any extent and whether or not substituted in the adamantyl ring to any extent, including the following: 2NE1, 5F-AKB-48, AB-001, APINACA and AKB-48, AM-1248, JWH-018 adamantyl carboxamide, STS-135;

(B) Benzoylindoles - any compound structurally derived from a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including the following: AM-630, AM-661, AM-679, AM-694, AM-1241, AM-2233, RCS-4 or SR-19, WIN 48,098 (Pravadoline);

(C) Cyclohexylphenols - any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the cyclohexyl ring to any extent, including, but not limited to, the following: CP 47,497, CP 47,497 C8 homologue, CP 55,490, CP 55,940, CP 56,667, cannabicyclohexanol;

(D) Cyclopropanoylindoles – any compound structurally derived from 3-(cyclopropylmethanoyl)indole, 3-(cyclopropylmethanone)indole, 3-(cyclobutylmethanone)indole or 3-(cyclopentylmethanone)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the cyclopropyl, cyclobutyl, or cyclopentyl rings to any extent;

(E) Naphthoylindoles – any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,

hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl group, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the naphthyl ring to any extent, including the following: AM-678, AM-1220, AM-1221, AM-1235, AM-2201, AM-2232, EAM-2201, JWH-004, JWH-007, JWH-009, JWH-011, JWH-015, JWH-016, JWH-018, JWH-019, JWH-020, JWH-022, JWH-046, JWH-047, JWH-048, JWH-049, JWH-050, JWH-070, JWH-071, JWH-072, JWH-073, JWH-076, JWH-079, JWH-080, JWH-081, JWH-082, JWH-094, JWH-096, JWH-098, JWH-116, JWH-120, JWH-122, JWH-148, JWH-149, JWH-164, JWH-166, JWH-180, JWH-181, JWH-182, JWH-189, JWH-193, JWH-198, JWH-200, JWH-210, JWH-211, JWH-212, JWH-213, JWH-234, JWH-235, JWH-236, JWH-239, JWH-240, JWH-241, JWH-242, JWH-258, JWH-262, JWH-386, JWH-387, JWH-394, JWH-395, JWH-397, JWH-398, JWH-399, JWH-400, JWH-412, JWH-413, JWH-414, JWH-415, JWH-424, MAM-2201, WIN 55,212;

(F) Naphthoylnaphthalenes – any compound structurally derived from naphthalene-1-yl-(naphthalene-1-yl) methanone with substitutions on either of the naphthalene rings to any extent, including CB-13;

(G) Naphthoylpyrroles - any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including the following: JWH-030, JWH-031, JWH-145, JWH-146, JWH-147, JWH-150, JWH-156, JWH-243, JWH-244, JWH-245, JWH-246, JWH-292, JWH-293, JWH-307, JWH-308, JWH-309, JWH-346, JWH-348, JWH-363, JWH-364, JWH-365, JWH-367, JWH-368, JWH-369, JWH-370, JWH-371, JWH-373, JWH-392;

(H) Naphthylmethylindenes - any compound containing a naphthylideneindene structure or that is structurally derived from 1-(1-naphthylmethyl)indene with

substitution at the 3-position of the indene ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including the following: JWH-171, JWH-176, JWH-220;

(I) Naphthylmethylindoles – any compound structurally derived from an H-indol-3-yl-(1-naphthyl) methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including the following: JWH-175, JWH-184, JWH-185, JWH-192, JWH-194, JWH-195, JWH-196, JWH-197, JWH-199;

(J) Phenylacetylindoles - any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including the following: Cannabipiperidiethanone, JWH-167, JWH-201, JWH-202, JWH-203, JWH-204, JWH-205, JWH-206, JWH-207, JWH-208, JWH-209, JWH-237, JWH-248, JWH-249, JWH-250, JWH-251, JWH-253, JWH-302, JWH-303, JWH-304, JWH-305, JWH-306, JWH-311, JWH-312, JWH-313, JWH-314, JWH-315, JWH-316, RCS-8, or SR-18;

(K) Quinolinylindolecarboxylates – any compound structurally derived from quinolin-8-yl-1H-indole-3-carboxylate by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-

2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the quinoline ring to any extent, including the following: BB-22, 5-Fluoro-PB-22, and PB-22;

(L) Tetramethylcyclopropanoylindoles – any compound structurally derived from 3-tetramethylcyclopropanoylindole, 3-(1-tetramethylcyclopropyl)indole, 3-(2,2,3,3-tetramethylcyclopropyl)indole or 3-(2,2,3,3-tetramethylcyclopropylcarbonyl)indole with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the tetramethylcyclopropanoyl ring to any extent, including the following: 5-bromo-UR-144, 5-chloro-UR-144, 5-fluoro-UR-144, A-796,260, A-834,735, AB-034, UR-144, and XLR11; and

(M) Tetramethylcyclopropane-thiazole carboxamides – any compound structurally derived from 2,2,3,3-tetramethyl-N-(thiazol-2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen atom of the thiazole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the thiazole ring to any extent, whether or not substituted in the tetramethylcyclopropyl ring to any extent, including A-836,339; and

(2) Unclassified Synthetic Cannabinoids:

(A) AM-087 (6aR,10aR)-3-(2-methyl-6-bromohex-2-yl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;

(B) AM-356 (methanandamide);

(C) (5Z,8Z,11Z,14Z)-N-[(1R)-2-hydroxy-1-methylethyl] icosa-5,8,11,14-tetraenamide; or arachidonyl-1'-hydroxy-2'-propylamide;

(D) AM-411(6aR,10aR)-3-(1-adamantyl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;

(E) AM-855(4aR,12bR)-8-hexyl-2,5,5-trimethyl-1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol;

(F) AM-905(6aR,9R,10aR)-3-[(E)-hept-1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol;

(G) AM-906(6aR,9R,10aR)-3-[(Z)-hept-1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol;

(H) AM-2389(6aR,9R,10aR)-3-(1-hexyl-cyclobut-1-yl)-6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9 diol;

(I) BAY38-7271(-)-(R)-3-(2-Hydroxymethylindanyl-4-oxy) phenyl-4,4,4-trifluorobutyl-1-sulfonate;

(J) CP 50,556-1 (Levonantradol);

(K) 9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate; or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5- phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-;

(L) octahydrophenanthridin-1-yl] acetate; or [9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate;

(M) HU-210(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-;

(N) (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; or [(6aR,10aR)-9-(hydroxymethyl) -6,6-dimethyl-3- (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; or 1,1-Dimethylheptyl- 11-hydroxytetrahydrocannabinol;

(O) HU-211 (Dexanabinol);

(P) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3- (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; or (6aS,10aS)-9-(hydroxymethyl) -6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;

(Q) HU-2433-dimethylheptyl-11-hydroxyhexahydrocannabinol;

(R) HU-308[(91R,2R,5R)-2-[2,6-dimethoxy-4- (2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol;

(S) HU-3313-hydroxy-2-[(1R,6R)-3-methyl-6- (1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione;

(T) JTE-907N-(benzol[1,3]dioxol-5-ylmethyl) -7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide;

(U) JWH-051((6aR,10aR)-6,6-dimethyl-3- (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-9-yl)methanol;

(V) JWH-057(6aR,10aR)-3-(1,1-dimethylheptyl) -6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-Dibenzo[b,d]pyran;

(W) JWH-133(6aR,10aR)-3-(1,1-Dimethylbutyl) -6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran;

(X) JWH-359 (6aR,10aR)- 1-methoxy- 6,6,9-trimethyl- 3-[(2R)-1,1,2-trimethylbutyl]- 6a,7,10,10a-tetrahydrobenzo[c]chromene;

(Y) URB-597[3-(3-carbamoylphenyl)phenyl] -N-cyclohexylcarbamate;

(Z) URB-602 [1,1'-Biphenyl]-3-yl-carbamic acid, cyclohexyl ester; or cyclohexyl [1,1'-biphenyl]-3-ylcarbamate;

(AA) URB-7546-methyl-2-[(4-methylphenyl)amino] -4H-3,1-benzoxazin-4-one;

(BB) URB-937 3'-carbamoyl-6-hydroxy-[1,1'-biphenyl]-3-yl cyclohexylcarbamate;

(CC) WIN 55,212-2(R)-(+)-[2,3-dihydro-5-methyl-3- (4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone; or [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[(1,2,3-de)-1,4-benzoxazin-6-yl]-1-napthalenylmethanone;

(DD) AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole); and

(EE) AM-694 (1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole).

(FF) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate ("PB-22"; QUPIC)

(GG) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate ("5-fluoro-PB-22"; 5F-PB-22)

(HH) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide ("AB-FUBINACA

(II) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide ("ADB-PINACA")

1202 SCHEDULE II ENUMERATED

1202.1 The controlled substances listed in this section are included in Schedule II of the Act unless removed therefrom pursuant to Section 201 of the Act:

(a) Unless specifically excepted or unless listed in another schedule, any of the following substances, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis;

(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, dextophan, nalbuphine, naltrexone, and their respective salts, but including the following:

(A) Codeine;

(B) Ethylmorphine;

(C) Etorphine Hydrochloride;

(D) Granulated opium;

(E) Hydrocodone;

(F) Tincture of opium;

(G) Hydromorphone;

(H) Metopon;

(I) Morphine;

(J) Opium extracts;

(K) Opium fluid extracts;

(L) Oripavine;

(M) Oxycodone;

(N) Oxymorphone;

(O) Powdered opium;

(P) Raw opium; and

(Q) Thebaine;

(2) Opium: Any salt, compound, derivative, or preparation thereof that is chemically equivalent or identical with any of the substances referred to in subparagraph (1) of this paragraph, but not including the isoquinoline alkaloids of opium;

(3) Opium poppy or poppy straw;

(4) Coca leaves, except coca leaves or extracts of coca leaves from which cocaine, ecgonine, or derivatives of ecgonine or their salts have been removed; cocaine, its salts, optical and geometric isomers, salts of isomers; or any compound, mixture, or preparation that contains any substance referred to in this paragraph;

(5) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid, or powder form that contains the phenanthrene alkaloids of the opium poppy); and

(6) Hashish;

(b) Opiates: Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation, dextrorphan excepted:

(1) 4-anilino-N-phenethyl-4-piperidine (ANPP);

(2) Alfentanil;

(3) Alphaprodine;

(4) Anileridine;

(5) Bezitramide;

(6) Bulk Dextropropoxyphene (non-dosage form);

(7) Carfentanil;

(8) Dihydrocodeine;

(9) Dihydroetorphine;

(10) Diphenoxylate;

(11) Fentanyl;

(12) Isomethadone;

(13) Levo-alphacetylmethadol [Some other names: levo-alpha-acetylmethadol, levomethadyl acetate, LAAM] ;

(14) Levomethorphan;

(15) Levorphanol;

(16) Metazocine;

(17) Methadone;

(18) Methadone-intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;

(19) Moramide-intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid;

(20) Pethidine (meperidine);

(21) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine; (Meperidine intermediate-A)

(22) Pethidine-Intermediate-B,ethyl-4-phenylpiperidine- 4-carboxylate; (Meperidine intermediate-B);

(23) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine- 4-carboxylic acid; (Meperidine intermediate-C)

(24) Phenazocine;

(25) Piminodine;

(26) Racemethorphan;

(27) Racemorphan;

(28) Remifentanil

(29) Sufentanil; and

(30) Tapentadol;

(c) Stimulants: Unless specifically excepted or unless listed in another schedule, any material compound, mixture, or preparation that contains

any quantity of the following substances having a stimulant effect on the central nervous system:

(1) Amphetamines, its salts, optical isomers, and salts of its optical isomers;

(2) Biphetamine

(3) Eskatrol

(4) Lisdexamfetamine

(5) Methylphenidate and its salts;

(6) Methamphetamine, its salts, isomers, and salts of isomers; and

(7) Phenmetrazine and its salts;

(d) Immediate precursors: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any

(1) Amphetamine/methamphetamine immediate precursor: phenylacetone (other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzyl ketone);

(2) Immediate precursor to fentanyl: 4-anilino-N-phenethyl-4-piperidine (ANPP); and

(e) Depressants: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Amobarbital;

(2) Glutethimide.

(3) Pentobarbital; and

(4) Secobarbital; and

(f) Hallucinogenic substances:

(1) Immediate precursors to phencyclidine (PCP):

(A) 1-phenylcyclohexylamine;

(B) 1-piperidinocyclohexanecarbonitrile (PCC); and

(2) Nabilone.